| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-15-0486 |
| P698 | PubMed publication ID | 26590165 |
| P50 | author | Carlo Stresemann | Q79794074 |
| Saskia A. Otto | Q122979719 | ||
| P2093 | author name string | Kathy A Gelato | |
| Silke Koehr | |||
| Georg Beckmann | |||
| Ralf Lesche | |||
| Patrick Steigemann | |||
| Henar Hernando | |||
| P433 | issue | 2 | |
| P921 | main subject | cell growth | Q189159 |
| multiple myeloma | Q467635 | ||
| P304 | page(s) | 287-298 | |
| P577 | publication date | 2015-11-20 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes | |
| P478 | volume | 15 |
| Q37709478 | Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells |
| Q90266389 | Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? |
| Q60922662 | DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling |
| Q42776492 | Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition |
| Q57806363 | Dual inhibition of EZH1/2 over-activates WNT signaling to deplete cancer stem cells in multiple myeloma |
| Q88619382 | Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS |
| Q59790124 | EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies |
| Q37705811 | EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. |
| Q55018505 | EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. |
| Q91520867 | EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation |
| Q39261435 | Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma |
| Q64088142 | Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease |
| Q37330876 | Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents |
| Q38740496 | Inhibitors of Protein Methyltransferases and Demethylases. |
| Q49869942 | Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma |
| Q88914220 | Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies |
| Q41760786 | Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. |
| Q92429871 | PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation |
| Q57035464 | PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs |
| Q26745416 | Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background |
| Q39379624 | Role of epigenetics-microRNA axis in drug resistance of multiple myeloma |
| Q90669066 | Seeking Convergence and Cure with New Myeloma Therapies |
| Q58586793 | Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds |
| Q39245946 | Structure of the PRC2 complex and application to drug discovery. |
| Q40968408 | Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors |
| Q38853857 | Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma |
| Q96348701 | The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma |
| Q38718857 | The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex |
| Q58718492 | The biological significance of histone modifiers in multiple myeloma: clinical applications |
| Q33838260 | The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma |
| Q47101382 | The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains |
| Q64075945 | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
| Q47098704 | UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition |
Search more.